ONCODESIGN | CORPORATE – initiation of coverage | EUR13
A diversified biopharmaceutical company. Oncodesign is a biotech company leveraging its powerful scientific capabilities, particularly on kinase inhibitors, through three different and complementary business activities: drug discovery services, partnerships with pharmaceutical companies in drug development, and the development of proprietary assets. The stock thus offers investors exposure to the potential upside of a traditional biotech company (through its own pipeline) with a lower risk profile, due to its diversified business model.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.